Zimmer Biomet’s SWOT analysis: stock faces challenges amid strategic acquisitions

Zimmer Biomet Holdings Inc (NYSE:ZBH), a leading player in the medical devices industry, has been making strategic moves to strengthen its market position and expand its product portfolio. With an "GREAT" financial health score according to InvestingPro analysis and a strong current ratio of 2.44, the company maintains robust operational stability. Currently trading near its 52-week low, ZBH faces a mix of opportunities and challenges as it navigates a complex business environment. This comprehensive analysis examines Zimmer Biomet’s recent performance, strategic initiatives, and future prospects.

Company Overview and Recent Acquisitions

Zimmer Biomet operates in the U.S. Medical (TASE:BLWV) Supplies & Devices sector, which currently holds a positive industry outlook. The company has been actively pursuing growth through strategic acquisitions. In a significant move, Zimmer Biomet recently announced plans to acquire Monogram Technologies, aiming to expand its enabling technology portfolio in the domain of active semi-automated and fully-automated robotic orthopedic surgery.

This acquisition is seen as potentially positive for the long term, suggesting that it could lead to significant advancements and growth in the company’s offerings in the future. However, analysts note that the deal is not considered to be thesis-changing in the near term, implying that it may not have an immediate impact on the company’s performance or valuation.

In another strategic move, Zimmer Biomet announced the acquisition of FNA for $1.1 billion in January 2025. This acquisition is aimed at expanding the company’s position in the $5 billion Foot & Ankle Orthopaedics market, further diversifying its product portfolio and increasing its presence in higher-growth markets.

Financial Performance and Outlook

Zimmer Biomet has demonstrated consistent growth in recent quarters, maintaining an impressive 71.2% gross profit margin over the last twelve months. The company’s fourth-quarter 2024 results were largely in line with expectations, showcasing a constant currency year-over-year sales growth just under 5%, marking the 12th consecutive quarter of mid-single-digit growth. The company has also maintained dividend payments for 14 consecutive years, demonstrating consistent shareholder returns. By division, knees grew by 5.6%, hips by 4%, and SET (Sports Medicine, Extremities, and Trauma) by 8.4%, leading to total sales of $2.02 billion.

For the fiscal year 2025, Zimmer Biomet has provided initial guidance predicting a 3-5% constant currency sales growth year-over-year and an adjusted earnings per share (EPS) growth of 3% at the midpoint, equating to $8.25. This forecast, however, does not account for the dilutive impact of the strategic acquisition of Paragon 28.

Product Portfolio and Innovation

Zimmer Biomet continues to focus on innovation and new product launches to drive growth. The company recently presented several innovations, including the OsseoFit Stemless Shoulder System. Additionally, Zimmer Biomet is preparing for the launch of two major knee products in the second half of 2025, which is expected to boost U.S. knee sales.

The company has also received positive feedback on its ROSA Shoulder robotic application, which supports its long-term growth potential in the robotic orthopedic surgery market.

Market Position and Competition

Zimmer Biomet maintains a strong position in its core markets, with healthy end markets supporting its growth. The company has appointed new presidents in all three core divisions, signaling a focus on strengthening its leadership and market strategies.

However, Zimmer Biomet faces challenges in its U.S. Knees business, which has shown weaker performance. The company is expected to navigate through these issues, with the upcoming product launches and favorable comparisons in the second half of 2025 anticipated to drive growth.

Long-Range Plan and Strategic Goals

Zimmer Biomet has outlined a Long Range Plan (LRP) with ambitious financial targets. The company aims for:

• Mid-single-digit year-over-year revenue growth rates
• EPS growth at 1.5 times the rate of revenue growth
• Free cash flow growth exceeding EPS growth by at least 100 basis points

These targets are set for 2024, 2025 (with some moderation due to one-time issues), and 2026. Achieving these goals could lead to improved financial returns and an expansion of the stock’s multiple. According to InvestingPro analysis, ZBH currently appears undervalued based on its Fair Value calculation, suggesting potential upside for investors. Want deeper insights? InvestingPro offers 6 additional exclusive tips and comprehensive analysis for ZBH, along with advanced valuation metrics and expert commentary.

Bear Case

How might tariffs and integration challenges affect ZBH’s profitability?

Zimmer Biomet faces significant headwinds from tariffs, which are expected to affect operating profit by $60 million to $80 million after mitigation efforts in the second half of 2025. The uncertainty regarding the impact of tariffs in 2026 adds to the challenge. Additionally, the company has reduced its free cash flow forecast by $350 million at the midpoint, attributed equally to tariffs and the acquisition of Paragon 28.

The integration of recent acquisitions, including Monogram Technologies and FNA, may also pose challenges. While these acquisitions are strategically important for long-term growth, they may not contribute immediately to financial performance and could potentially strain resources in the short term.

Can ZBH overcome the weakness in its U.S. Knees business?

The weaker performance in Zimmer Biomet’s U.S. Knees business remains a concern. While the company expects upcoming product launches to boost sales, the timing and market reception of these products are crucial. The success of these launches will be critical in overcoming the current weakness and maintaining the company’s competitive position in this important segment.

Bull Case

How could new product launches drive growth for ZBH?

Zimmer Biomet’s focus on innovation and new product launches presents a significant opportunity for growth. The upcoming launch of two major knee products in the second half of 2025 is expected to boost U.S. knee sales. Additionally, the OsseoFit Stemless Shoulder System and other innovations expand the company’s offerings in robust markets.

The positive feedback on the ROSA Shoulder robotic application further supports the company’s growth potential in the enabling technologies segment. These product launches could drive sales growth, improve market share, and potentially lead to margin expansion.

What potential does the acquisition of Monogram Technologies hold for ZBH?

The acquisition of Monogram Technologies positions Zimmer Biomet to become a leader in robotic orthopedic surgery technology over time. This move aligns with the growing trend towards minimally invasive and precision surgeries, potentially opening up new revenue streams and market opportunities.

While the acquisition may not have an immediate impact on the company’s thesis, it could significantly enhance Zimmer Biomet’s competitive position in the long term. The integration of Monogram’s technology with Zimmer Biomet’s existing portfolio could lead to innovative solutions that drive future growth and market leadership.

SWOT Analysis

Strengths

• Consistent mid-single-digit growth in core divisions
• Strong market position in orthopedic devices
• Innovative product portfolio, including robotic surgery technologies
• Strategic acquisitions expanding market presence

Weaknesses

• Weaker performance in U.S. Knees business
• Impact of tariffs on profitability
• Reduced free cash flow forecast

Opportunities

• Expansion in robotic orthopedic surgery through Monogram Technologies acquisition
• Growth in Foot & Ankle Orthopaedics market with FNA acquisition
• New product launches in knee and shoulder segments
• Long-term potential in enabling technologies

Threats

• Competitive pressures in core markets
• Regulatory challenges and potential changes in healthcare policies
• Economic uncertainties affecting healthcare spending
• Integration risks from recent acquisitions

Analysts Targets

• Barclays (LON:BARC): $112 (July 15th, 2025)
• Truist Securities: $101 (May 7th, 2025)
• JMP Securities: $125 (May 7th, 2025)
• JMP Securities: $140 (April 10th, 2025)
• Barclays: $112 (February 10th, 2025)
• JMP Securities: $140 (February 7th, 2025)
• Barclays: $118 (January 29th, 2025)
• Stifel: $138 (January 23rd, 2025)

This analysis is based on information available up to July 17, 2025, and reflects the complex landscape Zimmer Biomet navigates as it pursues growth through innovation and strategic acquisitions. For comprehensive insights into ZBH’s investment potential, explore the detailed Pro Research Report available on InvestingPro. This report is part of our coverage of 1,400+ top US stocks, offering institutional-grade analysis and actionable intelligence for smarter investing decisions.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on ZBH. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore ZBH’s full potential at InvestingPro.

Should you invest in ZBH right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if ZBH is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate ZBH further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if ZBH appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.